Abstract Details

Title Depression and Anxiety in Neuromyelitis Optica Spectrum Disease (NMOSD): Analysis of a National Dataset

Topic Autoimmune Neurology

Presentation(s) P10 - Poster Session 10 (11:45 AM-12:45 PM)

Poster/Presentation
Number 14-007

Objective Determine the frequency of depression and anxiety in a neuromyelitis optica spectrum disease (NMOSD) population pre and post NMOSD diagnosis.

Background NMOSD is an antibody-mediated autoimmune disorder affecting the central nervous system (CNS), mainly targeting the optic nerves and spinal cord. Increased rates of depression and anxiety have been recorded in relation to demyelinating diseases such as multiple sclerosis (MS). However, there is a dearth of literature on the prevalence of depression and anxiety in NMOSD pre diagnosis.

Design/Methods NMOSD diagnosis code was queried to form a de-identified aggregate dataset focused on United States patients: TriNetX is a global research network covering 68 US hospital systems. The NMOSD diagnosis dates range from 1992 to 2022. To increase specificity, patients who had less than three NMOSD ICD-10-CM (G36.0) code entries were removed. Additionally we only included patients with NMOSD related symptom ICD-10-CM diagnosis codes.

Results

1885 unique patients met the inclusion criteria for further analysis. Of this population 1444 (76.9%) were female, the median age was 50.75y [3.75 – 90.75], 968 (51.3%) were white, 591 (30.4%) were black, 62 (3.4%) were Asian, and 256 (14.4%) were unknown. For this population, 788 (42.8%) patients carried an anxiety and/or depression ICD-10-CM diagnosis code. 543 (28.81%) patients received a depression diagnosis. Of these 543 depression patients 317 (58.38%) were diagnosed before the NMOSD confirmation. 489 (25.94%) patients received an anxiety diagnosis. Of these 489 patients 295 (60.33%) received the diagnosis before their NMOSD confirmation.

Conclusions Depression and anxiety diagnoses are coded in approximately two-fifths of all NMOSD patients in the cohort; over half of whom were diagnosed with anxiety/depression before their NMOSD diagnosis. Given the complexities of the illness and its management, clinicians must be vigilant in remembering to query for depression and anxiety during patients visits.

Authors/Disclosures
Esther Zeng PRESENTER	Miss Zeng has nothing to disclose.
Abigail H. Sorenson	Ms. Sorenson has nothing to disclose.
Tammy L. Smith, MD, PhD (Imaging and Neurosciences Center)	Dr. Smith has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. The institution of Dr. Smith has received research support from Alexion/AstraZeneca.
Melissa A. Wright, MD (University of Utah)	Dr. Wright has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis .
Aditi Sharma (University of Utah)	No disclosure on file
Trieste Francis	Miss Francis has nothing to disclose.
John W. Rose, MD, FAAN (Imaging and Neurosciences Center)	The institution of Dr. Rose has received research support from National Multiple Sclerosis Society. The institution of Dr. Rose has received research support from Guthy Jackson Charitable Foundation. The institution of Dr. Rose has received research support from NIH . The institution of Dr. Rose has received research support from VA. The institution of Dr. Rose has received research support from Biogen. The institution of Dr. Rose has received research support from Friends of MS. Dr. Rose has received intellectual property interests from a discovery or technology relating to health care.
Ka-Ho Wong (U of U Neurology Clinic)	The institution of Mr. Wong has received research support from The Sumaira Foundation . The institution of Mr. Wong has received research support from The Siegel Rare Neuroimmune Association.
Stacey Clardy, MD, PhD, FAAN (University of Utah)	Dr. Clardy has received personal compensation for serving as an employee of Veterans Health Administration (VHA). Dr. Clardy has received personal compensation for serving as an employee of University of Utah Health. Dr. Clardy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca/Alexion. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen/Horizon. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arialys. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kyverna. Dr. Clardy has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology/AAN Publications. The institution of Dr. Clardy has received research support from NIH/NINDS. The institution of Dr. Clardy has received research support from SRNA. The institution of Dr. Clardy has received research support from Alexion/AstraZeneca. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving as a AAN Summer Meeting CoDirector Travel and Lodging with AAN. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving as a Grand Rounds Travel/Lodging/Honoraria with U of Iowa, Miami, Stanford, Barrow, Beaumont Health, CCF, Emory, Penn State, Mayo Clinic, Walter Reed.

��ɫ��

��ɫ��